MXPA97007911A

MXPA97007911A - Derivatives of amine 1- [w- (3,4-dihydro-2-naftalenil) rent] - cyclic, process for its preparation and pharmaceutical compositions that contain the mis

Info

Publication number: MXPA97007911A
Application number: MXPA/A/1997/007911A
Authority: MX
Inventors: Hino Katsuhiko; Kai Naoki; Kanehira Aki; Morie Thosiya; Kawashima Katsuyoshi; Shimizu Isao; Akiyama Kazuhisa
Original assignee: Dainippon Pharmaceutical Co Ltd
Priority date: 1995-04-15
Filing date: 1997-10-14
Publication date: 1998-11-09

Abstract

Derivative amine 1- [w- (3,4-dihydro-2-naphthalenyl) alkyl] cyclic of the formula (I): wherein R1 and R2 are H, halogen, OH, alkyl, alkoxy, hydroxymethyl, etc. OR R1 and R2 combine to form methylenedioxy, trimethylene, etc. R3 is H, etc., R4 is H, OH, alkyl, etc., R5 is H, alkyl, etc., p is an integer from 2 to 6, and q is an integer e 3 to 7, assuming that when p is 2, and q is 5, R1, R2, R3, R4 and R5 are not simultaneously H, or salts thereof, or an N-oxide derivative thereof, or a process for the preparation thereof, or a pharmaceutical composition which contains the same. The compounds of the present invention show a potent inhibitory effect on the myocardial reflex and are used as agents for the treatment of frequent urination to urinary incontinence

Description

DERIVATIVES OF AMIN 1- [í?) - (3, 4-DIHIDRO-2-NAFTALENIL) ALQUIL] -CÍCLICA, PROCESS FOR YOUR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THE SAME " FIELD OF THE INVENTION The present invention relates to a new cyclic alkylene derivative 1- £ G * - (3, 4-dihydro-2-naphthaleniDJ) which shows an inhibitory effect on the micturition reflex, a process for preparing it and a pharmaceutical composition containing them. contains them.

BACKGROUND OF THE ART Until now there are many reports about amine derivatives l - [α- (3,4-dihydro-2-naphthalenyl) alkyl] cyclical However, as far as the known reports of current inventors, amine derivatives l - [α- (3,4-dihydro-2-naphthalenyl) alkyl] cyclic are known in which the alkyl portion is ethyl, only the next time. That is, Pharmazie, 42, 369 (1987) discloses that l- [2 (3,4-dihydro-2-hydrochloride REP 25784 naphthalenyl) ethyljpiperidine shows a very low affinity for the dopamine receptor ip vi tro.

The following compounds are known as a amine derivative l - [? - (3,4-dihydro-2-naphthalenyl) alkyl] cyclic wherein the alkyl portion is a methyl.

USP 4,022,791 discloses that the compound of the following formula is employed as an analgesic and tranquilizing agent, and the role of almost the same content is reported in J. Med. Chem., 21, 257 (1978). wherein X and Y are independently H, F, Cl, Br, an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms, and Z is a secondary or tertiary amino group , provided that X and Y are not simultaneously H. In addition, Chem. Pharm. Bull., 31, 2006 (1983) describes that hypotensive activities and vasodilation of l - [(3,4-dihydro-6-morpholino-2-naphthalenyl) methyl] piperazine and 4-benzyl-l - [(3,4-dihydro-6-morpholino-2-naphthalenyl) methyl] piperidine were tested using dogs and hypertensive rats spontaneously.

With the arrival of the increase in the age of people in society, year after year the number of patients suffering from frequent urination and urinary incontinence tends to increase. At present, three drugs, namely flavoxate, oxybutynin and propiverine, are used clinically in the treatment of these conditions, in smaller quantities than drugs for treatment of frequent urination and urinary incontinence accompanied by prostatic heterotrophy. All these drugs expose their pharmacological activity (increases the capacity of the bladder volume) based on the relaxation of the smooth muscle of the bladder, and are not necessarily satisfactory in terms of less efficacy and difficulty for use in the case of frequent urination. urinary incontinence which is accompanied by urethral obstruction (difficulty in urination) as well as side effects.

Under the circumstances, the development of medications for the treatment of frequent urination and urinary incontinence via a central mechanism, which is different from current or existing medicines that have been tested. For example, 1-4 (-ethylphenyl) -2-methyl-3- (1-pyrrolidinyl) -1-propanone hydrochloride (generic name: inaperisone hydrochloride), which is a central muscle relaxant (cf., Drugs Fut., 18, 375 (1993)) have been reported to be effective for symptoms such as neurogenic bladder, unstable or irregular bladder, and neural polaquisuria (cf., Nishinihon J.Urol., 54, 1472 and 1820 (1992)). However, the improvement of the efficacy and side effects thereof may not necessarily be sufficient. The present inventors have studied intensively and have found that the amine derivative 1 - [α- (3,4-dihydro-2-naphthalenyl) alkyl] cyclic of the following formula (I) exhibits an immediate potent inhibitory effect mainly via a central mechanism in the reflection of the micturition, and some of the compounds (I) show their powerful inhibitory effect on the reflex of micturition without side effects such as depression in the central nervous system and inhibition of the spinal reflex.

DESCRIPTION OF THE INVENTION The present invention provides an amine derivative l - [α- (3,4-dihydro-2-naphthalenyl) alkyl] cyclic of the formula (I): wherein R1 and R2 are the same or different and each a hydrogen atom, a halogen atom, a hydroxy group, an alkyl group of 1-5 carbon atoms, an alkoxy group of 1-3 carbon atoms, a group hydroxymethyl, a formyl group, a carboxyl group, or an alkoxycarbonyl group of 1-3 carbon atoms, or when the R1 and R2 bonds with carbon atoms become adjacent to each other, then R1 and R2 they may be combined to form a methylenedioxy group, an ethyleneoxy group (-CH2CH20-), a trimethylene group or a tetramethylene group; R3 is a hydrogen atom, a halogen atom, a trifluoromethyl group, an alkyl group of 1-5 carbon atoms, an alkoxy group of 1-3 carbon atoms, or a phenyl group; R 4 is a hydrogen atom, a halogen atom, a hydroxy group, an alkyl group of 1-3 carbon atoms, or a methyl group (alkoxy of 1-2 carbon atoms); R5 is a hydrogen atom, a halogen atom, an alkyl group of 1-3 carbon atoms, or a methyl group (alkoxy of 1-2 carbon atoms); or when the bonds of R4 and R5 with a carbon atom different from the dreams become contiguous to the nitrogen atom, then R4 and R5 can combine to form an oxo group; p is an integer from 2 to 6; and q is an integer from 3 to 7, provided that when p is 2, and q is 5, then R 2, R 3, R 4, and R 5 are not hydrogen atoms simultaneously, a pharmaceutically acceptable acid addition salt thereof, and a derived from the same N-oxide, a process for the preparation thereof and a pharmaceutical composition containing them.

The pharmaceutically acceptable acid addition salt of the compound of the formula (I) includes a salt with an inorganic acid such as the hydrochloride, hydrobromide, hydroiodide, sulfate, or phosphate or a salt with an organic acid such as oxalate, malonate, succinate, maieate, fumarate, lactate, malate, citrate, tartrate, benzoate, methanesulfonate, or p-toluenesulfonate. The compound of the formula (I), a salt thereof and an N-oxide derivative thereof may exist in the form of a hydrate or a solvate, and the present invention also includes these hydrates and solvates.

The compound of the formula (I) may have one or more asymmetric carbon atoms, and / or exhibit geometric isomerism. Accordingly, the compound of the formula (I) can exist in the form of several stereoisomers. The present invention also includes these stereoisomers, a mixture thereof, and a racemic mixture thereof.

The terms used in the present description and the claims are explained below.

The alkyl group and the alkyl portion are any, either a straight open chain or a single branched chain. Halogen atoms include fluorine, chlorine, bromine and iodine, and fluorine and chlorine are preferable, and one more preferable is fluorine. Preferable groups for R 1 and R 2 are a hydrogen atom, a halogen atom (especially fluorine), a hydroxy group, a methyl group, an ethyl group, a propyl group, a methoxy group, an ethoxy group, a hydroxymethyl group, a carboxyl group, a methoxycarbonyl group, and an ethoxycarbonyl group. More preferable examples for R1 and R2 are a methyl group, an ethyl group, a methoxy group, an ethoxy group, and a hydroxymethyl group, and a linkage to position 6 and position 7 is preferable especially for these groups.

In addition to this, it is more preferable that R1 is a hydrogen atom or a halogen atom (fluorine in particular), and R2 is a halogen atom (fluorine in particular), and among them, 6,7-dihalogen or -halogen.

A preferable group for R3 is a hydrogen atom, and preferable groups for R4 are a hydrogen atom, a halogen atom (fluorine especially), a hydroxy group, and a methyl group, and among them are more preferable an hydrogen and a methyl group.

Preferable groups for R5 are a hydrogen atom and a methyl group. Additionally, it is preferable for R4 and R5 to combine and form an oxo group. Preferred "P" is an integer from 2 to 5, especially preferably 2.3, or 4, and more preferably 2. Especially the preferred "q" is 4 or 5, and more preferably 4. Preferred compounds of the present invention are compounds of the formula (I) wherein R1 and R2 are the same or different and each is a hydrogen atom, a halogen atom, a hydroxy group, a methyl group, and an ethyl group, a propyl group, a methoxy group , an ethoxy group, a hydroxymethyl group, a carboxyl group, a methoxycarbonyl group, or an ethoxycarbonyl group, R3 is a hydrogen atom, and R4, R5, p and q are the same as defined above, an acid addition salt thereof pharmaceutically acceptable, and an N-oxide derivative thereof.

More preferable compounds of the present invention are the compounds of the formula (I) wherein the R 1 and R 2 bonds at position 7, and position 6, respectively, are the same or different, and each a methyl group, an ethyl group, a methoxy group, an ethoxy group, or a hydroxymethyl group, R3 is a hydrogen atom, R4 and R5 are the same or different and each a hydrogen atom, or a methyl group, p is an integer from 2 to 5, and q is an integer from 3 to 7, and a pharmaceutically acceptable acid addition salt thereof.

Other more preferable compounds are the compounds of the formula (I) wherein R 1 is a hydrogen atom, R 2 is a 5-halogen atom, or R 1 and R 2 are each a halogen atom at the 7-position and 6-position, respectively , and R3 is a hydrogen atom, R4 and R5 are the same or different and each a hydrogen atom or a methyl group, p is an integer from 2 to 5, and q is an integer from 3 to 7, and a pharmaceutically acceptable acid addition salt thereof.

The most preferable compounds are the compounds of the formula (I) wherein the R 1 and R 2 bonds at position 7 and position 6, respectively, are the same or different and each a methyl group, an ethyl group, a methoxy group, a ethoxy group, or a hydroxymethyl group, all of R3, R4, and R5 are hydrogen atoms, p is 2.3 or 4, and q is 4 or 5, and an acid addition salt thereof, pharmaceutically acceptable.

Other more preferable compounds are the compounds of the formula (I) wherein R 1 is a hydrogen atom, R 2 is a 5-fluorine atom, or R 1 and R 2 are 7-fluorine atoms and 6-fluorine atoms, respectively, all of R3, R4 and R5 are hydrogen atoms, p is 2, 3 or 4 and q is 4 or 5, and a pharmaceutically acceptable acid addition salt thereof. Especially preferred compounds are the compounds of the formula (la): , x? and • O (the) wherein R and a are the same or different and each a methyl group, an ethyl group, a methoxy group, an ethoxy group, or a hydroxymethyl group, and a pharmaceutically acceptable acid addition salt thereof.

Suitable examples of the most preferable compounds of the present invention are the following compounds and a pharmaceutically acceptable acid addition salt thereof, and among them, four preceding compounds are more preferable, and especially the two preceding compounds are most preferable. l- [2, (3,4-Dihydro-6,7-methyl-2-naphthalenyl) ethyl] pyrrolidine, 1- [2- (5-fluoro-3,4-dihydro-2-naphthalenyl) ethyl] pyrrolidine, l- [2- (3,4-Dihydro-6,7-dimethoxy-2-naphthalenyl) ethyl] pyrrolidine, l- [2- (3,4-Dihydro-7-methoxy-6-methyl-2-naphthalenyl) ethyl] pyrrolidine, l- [2- (3,4-Dihydro-6-hydroxymethyl-7-methyl-2-naphthalenyl) ethyl] pyrrolidine, l- [2- (6,7-Diethyl-3,4-dihydro-2-naphthalenyl) ethyl] pyrrolidine, l- [2- (6,7-difluoro-3,4-dihydro-2-naphthalenyl) ethyl] pyrrolidine, and l- [2- (3,4-dihydro-6,7-dimethyl-2-naphthalenyl) ethyl] piperidine.

Representative compounds of the present invention are, in addition to the compounds of the Examples described herein, the compounds of the following Tables 1 and 2, and a pharmaceutically acceptable acid addition salt thereof, and an N-oxide derivative thereof. . In the tables, Me means a methyl group, and Et means an ethyl group.

Table 1 R1 R < RJ R "Rb P 7 -. 7 -. 7 -. 7 -. 7 -. 7 -. 7 -. 7 -. 7 -. 7 -. 7 -. 7 -. 7 -. 7 -. 7 -. 7 -. 7 -Me 6 -Me H 2 -Me H 2 7 -Me 6-Me H 0 = (position 3) 2 7 -Me 6 -Me H H H 3 7 -Me 6 -Me H H 4 6-Me 5 -Me H H 2 8 -. 8 -. 8 -. 8 -. 8 -. 8 -. 8 -Me 5 -Me H H 2 8 -Me 6 -Me H H H 2 8 -Me 7 -Me H H 2 6-Et 5-Et H H H 4 7-Et 5-Et H H H 2 7 -Me 6 -Me 8 -Me H H 2 7 -Me 6 -OMe H H H 2 H 6 -Me H H H 2 8 -Me H H H 2 H H 7-CF3 H H 2 H 5-F H 2 -Me H 2 H 5-F H H H 3 H 5-F H H H 4 H 5-F H 2 -Me 5 -Me 2 H 5 -F H 3 -F 3-F 2 Table 2 R? _____ 8-F H H 6-C1 H H H 5-Br H 8-F 7-F H 7 -OMe 6-F H 7 -OMe 6 -Me 5-F 7 -Me 6 -OMe 5-F 7 -Me 6 -Me 5-F 7 -OMe 6-OMe 5-F 8 -OMe 7 -OMe H 8 -OMe 5 -OMe H 7 -OMe 5 -OMe H 6 -. 6 -. 6 -OMe 5 -OMe H 6-OCH 2 O-5 H 8 -OCH 2 O-7 H 6-CH2OH H H 7-CH2OH 6-Me H 6-COOH H H 7 -COOH 6-Me H 6 -COOMe H H 7 -COOMe 6 -Me H 7 -Me 6-COOMe H 7-CH2OH 6-CH2OH H 7 -COOH 6-COOH H The compounds of the present invention can be prepared, for example, by the following procedure: Process (a): The compound of the formula (i) is prepared by subjecting a compound of the formula (II): wherein R1, R2, R3, R4, R5, p and q are the same as defined above, by dehydration.

The dehydration reaction is carried out under the conditions which become convenient for the dehydration reaction of an alcohol in an olefin. For example, react the compound of the formula (II) with a dehydrating agent in a convenient solvent or without a solvent. Dehydrating agents include, for example, an inorganic acid (eg, hydrogen chloride, hydrogen bromide, sulfuric acid, phosphoric acid, or boric acid), an organic acid (eg, oxalic acid, formic acid, or trifluoroacetic acid) , an aromatic sulfonic acid (for example, p-toluenesulfonic acid), an organic acid anhydride (for example acetic anhydride), o-sulfobenzoic anhydride, an anhydrous inorganic salt (for example, potassium hydrogen sulfate), an acid chloride inorganic (for example, thionyl chloride or phosphorus oxychloride), an organic acid chloride (for example, acetyl chloride), a sulfonic acid chloride (for example, p-toluene sulphonyl chloride or methanesulfonyl chloride), an acid Lewis (for example, boron, the complex of fluorine diethyl ether or zinc chloride), iodine, alumina, and silica gel. The solvents may be selected in accordance with, for example, the types of dehydrating agents to be used, and include, for example, aromatic hydrocarbons (e.g., benzene, toluene, and xylene) ethers (e.g., diethyl ether, tetrahydrofuran or dioxane), ketones (for example acetone or methyl ethyl ketone), acetonitrile, alcohols (for example, methanol, ethanol or isopropyl alcohol) ethylene glycol, organic acids (for example (formic acid, acetic acid propionic acid) pyridine, dimethylsulfoxide and water. These solvents can be used alone, or in mixtures of two or more solvents The temperature of the reaction can vary, depending, for example, on the types of dehydration agents, but they are commonly in the range of about -20 ° C to about 200 ° C. In addition, the compound of the formula (II) used in the dehydration reaction can be in the form of a compound with a reducing agent containing boron. or such as boranes or a disintegrated product thereof, which can be converted to the compound of the formula (I) by using an acidic dehydrating agent such as an inorganic acid or an organic acid.

The initial compounds (II) can be prepared by the procedures of the following reaction schemes.

(V) (IV) (VI) (ID wherein R3, R4, R5, p and q are the same as defined above, R1 and R2 are the same groups as those for R1 and R2, except that the formyl group and the carboxyl group are the protected ones.

In the reaction of the above scheme, the protective formyl group for R1 and R2 includes for example, acetals (for example, methyl dimethoxy, methyl diethoxy, or methyl ethylenedioxy), oximes, (for example hydroxymethylene) and the protective carboxyl group which includes example, a lower alkoxycarbonyl group (e.g. methoxycarbonyl or ethoxycarbonyl) an aralkyloxycarbonyl group (e.g., benzyloxycarbonyl).

Each of the steps of the above reaction scheme is explained below.

Step 1 The present step is carried out by reacting the compound (V) or a reagent derived therefrom with the compound (IV) under the same conditions for the conventional amidation reaction.

The reagent derived from the compound (V) includes, for example, a lower alkyl ester (especially methyl ester), an activated ester, an anhydride acid, and a halide acid (especially a chlorinated acid). The activated esters include, for example, p-nitrophenyl ester, 2, 4, 5-trichlorophenyl ester, and N-hydroxysuccinimide ester. The acid anhydride includes a symmetrical acid anhydride and a mixed acid anhydride, and the mixed acid anhydride includes, for example, an acid anhydride mixed with an alkyl chlorocarbonate such as ethyl chlorocarbonate or isobutyl chlorocarbonate, a acid anhydride mixed with an aralkyl chlorocarbonate such as benzyl chlorocarbonate, and an acid anhydride mixed with an aryl chlorocarbonate such as the phenyl chlorocarbonate, and an anhydride acid mixed with an alkanoic acid such as isovaleric acid or pivalic acid .

When the compound (V) per se is used in this step, it is preferable to carry out the reaction in the presence of a condensing agent such as N, N'-dicyclohexylcarbodiimide, l-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride. , N, N'-carbonyldiimidazole, N, '-carbonyldisuccinimide, l-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, diphenylphosphoryl azide, propanephosphonic anhydride or benzotriazol-1-yloxy tris (dimethylamino) -phosphonium hexafluorohydrophosphate.

The reaction of the compound (V) or a reagent derived therefrom with the compound (IV) is carried out in a solvent or without a solvent. The solvent may be selected in accordance with, for example, the types of initiator compounds to be used, and include for example, aromatic hydrocarbons (e.g., benzene, toluene and xylene) ethers (e.g. diethyl ether, terhydrofuran, and dioxane) ), halogenated hydrocarbons (e.g., dichloromethane and chloroform), alcohols (e.g., ethanol and isopropyl alcohol) ethyl acetate, acetone, acetonitrile, dimethylformamide, 1,3-dimethyl-2-imidazolidinone, dimethyl sulfoxide, ethylene glycol , and water. These solvents can be used alone or in a mixture of two or more solvents. The reaction is optionally carried out in the presence of a base, if necessary, and the base includes, for example, an alkali hydroxide (e.g., sodium hydroxide or potassium hydroxide), an alkali carbonate (e.g. sodium carbonate or potassium carbonate), an alkali hydrogen carbonate (for example sodium hydrogen carbonate or potassium hydrogen carbonate) or an organic base (for example, triethylamine, tributylamine, diisopropylethylamine or N-methylmorpholine) but an excessive amount of compound (IV) can act in place of a base. The temperature of the reaction may vary depending, for example, on the types of initial compounds used, but is usually in the range of about -30 ° C to about 200 ° C, preferably in the range of about -10 ° C to about 150 ° C.

The starting compound (V) of this step can be prepared from 3,4-dihydro-l (2H) -naphthalenones by a method known per se, for example, by the method disclosed in J.Med.Chem., 17 , 273 (1974); Japanese Patent First Publication (Kokai) No. 54-24861 (Chem. Abstr., 91, 56702b (1979)); Pharmazie, 41, 835 (1986); Yakugaku Zassi, 110, 561 and 922 (1990); Heterocycles, 34, 1303 (1992); Tetrahedron, 48, 4027 (1992), or the procedures described in Reference Examples 1 to 3, or by a modified procedure thereof. Otherwise, the initiator 3, 4-dihydro-l (2H) -naphthalenones for preparing the compound (V) may be commercially convenient once, or may be prepared by a method known per se, for example, by the method described in J. Chem. Soc., 1961, 4425; J. Org.

Chem., 26, 1109 (1961); J. Heterocycl .Chem. , 10, 31 (1973); USP 4,022,791; Chem. Pharm. Bull., 25, 632 (1977); ibid., 31, 2006 (1983); J. Med. Chem., 17, 273 (1974); ibid., 50, 4933 (1985); Japanese Patent First Publication (Kokai) No. 6-87746; Synth Commun., 21, 981 (1991); or Tetrahedron Lett., 33, 5499 (1992), or by a modified method thereof.

The other starting compounds (IV) of this step can be obtained once commercially, or they can be prepared by a method known per se, for example, by the method described in Synlett, 1995,55, or by a modified method thereof.

The compound of formula (VI) wherein p is 2 is also prepared by the methods of paragraphs (1) to (3) of Reference Example 9 or 12 described herein, or by a method modified by itself.

Step 2 The present step is carried out by treating the compound (VI) with a reducing agent being convenient to reduce a carbonyl group of ketone in a hydroxyalkyl group, and reduce a carbonyl group of amide in a methylene group in a convenient solvent. The reducing agent includes, for example, a hydrido compound or an aluminum hydride such as lithium aluminum hydride, diisobutyl aluminum hydrido, sodium bis (2-methoxyethoxy) sodium hydride, or aluminum hydride, sodium borohydride, or a combination of sodium borohydride with a Lewis acid such as an aluminum chloride anhydride, cobalt (II) chloride, or a boron fluoride-diethyl ether compound, a boron hydrogen compound such as sodium acetoxyborohydride or sodium trifluoroacetoxyborohydride, borates such as diborane, and triethylsilane-zin chloride. The solvent can be selected according to, for example, the types of reducing agents to be used, and includes, for example, ethers (for example, diethyl ether, tetrahydrofuran, dimethoxyethane, dioxane, and diglyme) aromatic hydrocarbons (for example, benzene) and toluene) halogenated hydrocarbons (for example dichloromethane and chloroform), alcohols (for example methanol and ethanol) acetic acid, and pyridine.

These solvents can be used alone, or in a mixture of two or more solvents. The reaction temperature may vary depending, for example, on the types of reducing agents used, but is usually in the range of about -10 ° C to about 130 ° C. The reduction reaction can be carried out under conditions of inert atmosphere, for example, under nitrogen gas or argon gas. When the compound (VI) wherein R4 and R5 combine to form an oxo group used in this step, it is preferable to protect said group prior to the reaction with a conventional protecting group such as an acetal (e.g., acetal dimethyl, acetal diethyl) , or acetal ethylene), or an oxime. When the compound (VI) is used wherein R1 and / or R2 are formyl protecting groups and / or a carboxyl protecting group, the protecting groups in the product are removed by a conventional method after the reduction gives the compound (II) . The compound (II) obtained in this step can be used in the aforementioned subsequent dehydration reaction without isolation or purification. When a reducing agent containing boron such as boranes is used as a reducing agent, the compound (II) is obtained in the form of a compound with a reducing agent containing boron or a disintegrated product thereof, which can be used as it is in the dehydration reaction mentioned above.

Procedure (B); The compound of the formula (I) is also prepared by reacting a compound of the formula (III): wherein R1, R2 'R3 and p are the same as defined above, X and Y are the same or different and each a reactive ester residue of an alcohol, and Z is a hydrogen atom, or Y and Z can combine to form a bond with a compound of the formula (IV): wherein R4, R5 and q are the same as defined above.

The reactive ester residue of an alcohol for X and Y of the formula (III) includes, for example, a halogen atom (for example chlorine, bromine, or iodine), a lower alkylsulfonyloxy group (for example methanesulfonyloxy or ethanesulfonyloxy), and an arylsulfonyloxy group (e.g., benzenesulfonyloxy, p-toluenesulfonyloxy, or m-nitrobenzenesulfonyloxy).

The reaction of the compound (III) and the compound (IV) is usually carried out in the presence of a base in a convenient solvent. The base includes, for example, an alkyl carbonate (e.g., sodium carbonate or potassium carbonate), an organic base (e.g., triethylamine, tributylamine or diisopropylethylamine or N-methylmorpholine), and an alkali metal hydride (e.g. sodium hydride or potassium hydride), but an excessive amount of the compound (IV) may act in place of a base. The solvent can be selected according to, for example, the types of the initiator compounds and the bases to be used, and include for example, aromatic hydrocarbons (for example benzene and toluene), ethers (for example tetrahydrofuran, dioxane and diglyme) halogenated hydrocarbons (for example dichloromethane and chloroform), ketones (for example acetone and ethylmethyl ketone), acetonitrile, alcohols (for example methanol, ethanol and isopropyl alcohol), dimethylformamide, and 1,3-dimethyl-2-imidazolidinone. These solvents may be used alone, or in a mixture of two or more thereof. The reaction temperature may vary depending, for example, on the types of initiator compounds to be used, and this is usually in the range of about 30 ° C to about 150 ° C, preferably in the range of about 80 to about 120 ° C. C.

The initiator compound (III) is prepared by methods known per se, for example, by the method of Reference Examples 10 and 11 described at this point or by a modified method thereof.

When the compound (I) wherein R1 and / or R2 are alkoxycarbonyl groups of 1-3 carbon atoms are obtained in the above process (a) or (b), said compound (I) can be converted to the compound ( I) wherein R1 and / or R2 are a formyl group or a hydroxymethyl group by reduction in a conventional manner, or in compound (I) wherein R1 and / or R2 are a carboxyl group by hydrolysis in a conventional manner. The conversion within the hydroxymethyl group is illustrated in Example 71 described at this point. The conversion to the carboxyl group is illustrated in Example 73. Conversion to the formyl group is carried out by reduction at a temperature from about -78 ° C to about -50 ° C when a hydride or a complex of aluminum hydrogen (eg, lithium aluminum hydride, diisobutyl aluminum hydride, or sodium aluminum hydride bis (2-methoxyethoxy) as a reducing agent The compound (I) obtained in the above process can be isolated and purified by a conventional method such as by chromatography, recrystallization or reprecipitation Compound (I) is obtained either in the form of a free base or in the form of an acid addition salt thereof, in accordance with the types of initiator compounds, reaction conditions, etc. The acid addition salt is converted to a free base by a conventional method, for example, by treatment with a base (eg, alkali carbonate or alkali hydroxide). Otherwise, the free base can be converted to an acid addition salt thereof by treatment with various acids by a conventional method.

In addition, the compound (I) can be converted to an N-oxide derivative to the cyclic amine portion thereof by oxidation under conventional N-oxidation conditions. The N-oxidation reaction is carried out by reacting the compound (I) with an oxidizing agent in a convenient solvent. Oxidizing agents include, for example, hydrogen peroxide and organic peracids such as peracetic acid, benzoic acid, m-chloroperbenzoic acid, and mono-perhthalic acid. The oxidizing agent is usually used in an amount of about 0.9 to about 2 equivalents, to the amount of the compound (I). The solvent can be selected according to, for example, the types of oxidizing agents used, and include, for example, water, acetic acid, alcohols (for example, methanol and ethanol), ketones (for example ketones), ethers (e.g. diethyl ether and dioxane), and halogenated hydrocarbons (for example, dichloromethane and chloroform). The reaction temperature may vary depending, for example, on the types of oxidizing agents used, and are usually in the range of about -30 ° C to about 100 ° C, preferably in the range of about -20 ° C to about 30. ° C.

The pharmacological activities of the compounds of the present invention are illustrated by the following pharmacological experiments on the representative compounds of the present invention, and on the inaperisone hydrochloride (herein, optionally referred to as "Compound A"), which is a known agent which acts centrally for the treatment of frequent urination and urinary incontinence.

Experiment 1 Inhibitory effect on rhythmic contractions of the bladder (reflex of micturition) The experiment was carried out according to the method of Maggi, C.A. and Meli, A. [J: Pharmacol.Methods, 10, 79 (1983)]. It is generally accepted that the rhythmic contractions of the bladder evoked by the instillation of saline solution within the bladder are mediating via the micturition reflex, a path similar to that of natural urination.

Female Std-Wistar rats weighing 160-190 g were used in groups of 3-4 animals. Under urethane anesthesia (1 g / kg, s.c.) both uteri were attached and cut laterally to the kidney after a half line of incision in the abdomen. A probe connected to the kidney was inserted through the external urethral orifice. a syringe and a pressure transducer and ligated around the proximal urethra. The animal remained that way for approximately 30 minutes after the operation. The bladder was slowly emptied with heated saline (0.4-1 ml) by means of a syringe to induce rhythmic contractions. The change in intravesicular pressure was recorded on a recorder via pressure transducer. After the rhythmic contractions were constant, the test compounds were dissolved or suspended in 0.5% aqueous tragacanth solution, administered via the inserted probe by intraduodenal administration. The effect of each compound on the contractile frequency was investigated every 15 minutes even two hours after administration.

Table 3 shows the inhibitory effect on the contractile frequency (two hours) at prescribed doses of each test compound or the doses of compound test required for 50% inhibition of the contractile frequency (ED50 value). The inhibitory rate in the contractile frequency (two hours) was expressed as the mean value of the inhibitory rates at a 15-minute interval for two hours after administration, which was determined based on the contractile frequency for 15 minutes before the administration. administration. The ED50 value was determined by the Litchfield-Wilcoxon method [J. Pharmacol. Exp. Ther., 96, 99 (1949)] based on the rates of inhibitory frequency (two hours) contractile at each dose.

Table 3 Inhibitory effect on rhythmic contractions of the bladder.

Test Inhibitory effect on the test Inhibitor effect io on the contractile frequency frequency against Comp. Comp. ED 50 (mg / kg, i.d) 0 doses; DE50 < mg / kg, i.d 0 dose; inhibitory percentage (%) inhibitory percentage (%) Ex.l ED5o = 4.3 mg / kq Ex.43 EDso ^ ll.l mg / kq Ex.2 EDso = 4.4 mg / kg Ex.44 10 mg / kg; 3. 4% Ex.3 10 mg / kg; 38% Ex.45 10 mg / kg; 48% Ex.4 ED5o = H.4 mg / kg Ex.46 ED50 = 12.4 mg / kg Ex.6 10 mg / kg; 42% Ex.47 10 mg / kg; 37% Ex.8 30 mg / kg; 62% Ex.49 10 mg / kg; 46% Ex.9 10 mg / kg; 47% Ex.50 10 mg / kg; fifty% Ex.10 10 mg / kg; 33% Ex.52 10 mg / kg; 52% Ex.11 30 mg / kg; 60% Ex.53 10 mg / kg; 35% Ex.12 10 mg / kg; 35% Ex.54 10 mg / kg; 43% Ex.13 30 mg / kg; 77% Ex.55 10 mg / kg; 43% Ex.14 10 mg / kg; 49% Ex.56 10 mg / kg; 34% Ex.15 10 mg / kg; 44% Ex.58 10 mg / kg; 34% Ex.18 30 mg / kg; 51% Ex.60 10 mg / kg; 33% Ex.20 30 mg / kg; 67% Ex.62 ED50 = 6.1 mg / kg As is clear from Table 3, all of the compounds of the present invention tested in this experiment markedly expose the inhibitory effects on the frequency of rhythmic contractions of the bladder. Especially the effects on the compounds of Examples 1 and 2, which were about 8 times more potent than those with inaperisone hydrochloride (Compound A). Additionally, the effects on the compounds of examples 62.68, 4, 36 and 43 were approximately 5.7, 4.7, 3.3 and 3 times more potent compared to those of inaperisone hydrochloride respectively.

In addition, the compounds of Examples 2, 3, 4, 12, 20, 26, 36, 41, 43-47, 49, 50, 56, 62, 68 and 72 not only expose the inhibition of contractile frequency, but also they suppress the amplitude of the contraction.

Experiment 2 Effect on contractions of the bladder induced by pelvic nerve stimulation.

Std- istar male rats weighing 250-350 g were used. Under urethane anesthesia (1 g / kg, ip) both uteri were attached and cut laterally to the kidney after a midline incision in the abdomen. When the peripheral end of the pelvic nerve was stimulated, one side of the pelvic nerve was cut off. When the end of the central cut of the nerve was stimulated, one side of the pelvic nerve was cut similarly to the peripheral end and then both stimulations of the hypogastric nerve were cut. Then, the bladder was exposed, the probe connected to a syringe and a pressure transducer, was inserted into the bladder via a small incision at one apex of the abdomen, and then the proximal urethra was ligated. Fifteen minutes after the operation, a warm saline solution in an amount (0.1-0.2 ml) being small enough not to cause rhythmic contraction, was introduced into the bladder using a syringe.

The change in intravesical pressure was recorded on a recorder via a pressure transducer. The pelvic nerve was stimulated and cut to the final periphery or center once by a pair of platinum electrodes with pulses of duration 1 msec, 3v force and a frequency of 10 Hz (per periphery) or 5 v of force and a frequency of 20 Hz (per center), for 5 seconds every 2 minutes. The test compounds dissolved in distilled water were injected at a dose of 5 mg / kg via the probe inserted into the jugular vein.

Table 4 shows the inhibitory rate of the test compounds in the contractions at 2.40, 10 and 20 minutes after the administration of the test compounds which was calculated as compared to the control response before the administration of the compound test, and was compared with those of the vehicle (distilled water) and treated group (unpaired t-test). Each value in the table is medium + standard error of males in 3-4 animals.

Table 4 Effect on bladder contractions induced by pelvic nerve stimulation Test.Comp. Inhibitory percentage (%) in Test. Comp. contractions caused by stimulation of the cut end in the periphery 2 min 4 min. 10 min 20 min Control -4.1 + 7.4 -2.4 + 7.5 3.0 + 5.0 6.6 + 8.1 Ex.l 4.4 + 4.4 3.4 + 4.4 3.2 + 7.5 9.6 + 8.6 Ex.2 0.4 + 5.2 16.3 + 7.0 13.7 + 4.5 19.0 + 7.5 Ex.43 2.4 + 3.3 5.8 + 6.3 6.3 + 8.1 17.2 + 12.2 Comp.A 6.2 + 5.1 14.7 + 4.0 25.1 + 4.2 * 31.6 + 2.5 * Test.Comp. Inhibitory percentage () in the ComD Test contractions caused by the stimulation p * of the cut end in the center 2 min 4 min. 10 min 20 min Control -8.1 + 5.0 -1.4 + 5.1 -1.5 + 11.6 1.7 + 9.2 Ex. 1 26.3 + 10.0 * 27.6 + 5.6 ** 36.8 + 10.1 44.1 + 5.8 ** Ex.2 13.3 + 5.1 * 17.7 + 2.8 * 25.6 + 3.7 ** 24.9 + 4.1 Ex.43 6.0 + 10.8 22.8 + 9.7 28.3 + 4.0 37.3 + 5.0 * Comp.A 21.0 + 10.7 * 22.5 + 7.3 * 29.3 + 7.7 40.6 + 8.8 * [note]: *: p < 0.05, **: < 0.01 (compared to the group of control, studying t-test) As is clear from Table 4, the effects of the compounds of Examples 1, 2 and 43 on bladder contractions induced by stimulation of the central and final cut were more potent than those in contractions induced by stimulation of the bladder. cut in the final periphery. The result arises that the effects of the compounds of the invention can be measured immediately via the central nervous system.

Experiment 3: Inhibitory effect on exploratory operation. Male Std-Wistar rats weighing 150-200 g were used in groups of 5 animals. One hour after oral administration of the test compounds suspended in 0.5% aqueous tragacanth solution, the animals were placed individually in a test box (23x35x30 cm) in an Animex activity counter (Farad Co., Switzerland). Immediately afterwards, the counting machine was started and continued for three minutes.

The mean value of the exploratory operation (cont / 3 minutes) in the test compound was determined with the treated groups, and the inhibitory effect of each test compound was calculated compared to that of the control group (0.5% aqueous tragacanth solution per group). treated). The results are shown in Table 5 together with the results of experiments 4 and . Experiment 4: Inhibitory effect on the polysynaptic spinal reflex.

The experiment was carried out in accordance with the method of Itoh, et. to the. [Japan J. Pharmacol., 23, 1125 (1982)]. Male Std-Wistar rats weighing 250-350 g were used in groups of 4-6 animals. Under anesthesia combined with i.p. urethane injection (400 mg / kg) and a-chloralose (50 mg / kg), rats fixed in a stereotactic apparatus were screwed to the spine and tibia. A concentric needle electrode was inserted into the left gastronemius muscle, and the final end of the common peroneal nerve ipsilateral to the same side was stimulated supramaximally by an electrical stimulator (rectangular pulse, 0.1 msec, 0.1 Hz). The test compounds dissolved in distilled water were injected via the inserted probe into the right femoral vein, and the evoked electromyogram was recorded periodically (2, 5, 10, 20 and 30 minutes after the injection). The inhibitory effect of the test compounds on the amplitude of the evoked electromyogram was expressed as a percentage against the amplitude before administration and then, the ID50 value (the dose required for 50% inhibition of amplitude) was calculated in accordance with the Litchfield-ilcoxon method based on the maximum inhibitory ratio at each dose. The results are shown in table 5 together with the results of experiments 3 and 5. Experiment: 5 Acute toxicity Male ddY mice weighing between 18-25 g were used in groups of 5-15 animals. The test compounds were suspended in 0.5% aqueous tragacanth solution administered orally, and mortality was investigated for 7 days followed by administration. The LDso value (50% lethal dose) was calculated according to the Litchfield-Wilcoxon method. The results are shown in Table 5 together with the results of experiments 3 and 4.

Table 5 Inhibitory effect on exploratory functioning, inhibitory effect on the polysynaptic spinal reflex and acute toxicity.

Test. Inhibitory effect on Toxicity effect the acute inhibitory exploratory function in the reflex Comp. spinal polysynaptic Dosage (p.o) percent. ID50 (i.v.) LD50 (p.o) Inhibit. (%) Ex.l 500 mg / kg 16.2% > 10 mg / kg 556 mg / kg Ex.2 500 mg / kg 0% > 8 mg / kg 620 mg / kg Ex.43 500 mg / kg 20.0% 3.82 mg / kg 1043 mg / kg Comp. 500 mg / kg 28.3% 4.22 mg / kg 458 mg / kg As is clear from Table 5, the inhibitory effects of the compounds of Examples 1 and 2 on the exploratory operation were less potent than those of compound A, and the inhibitory effect of the compound of Example 43 on the exploratory operation was almost the same as that of compound A. In the spinal reflex experiment, the inhibitory effect of the compound of Example 43 was about the same as compound A, but the effects of the compounds of examples 1 and 2 were more deficient than those of compound A. The acute toxicity of the compound of Example 43 was approximately two times smaller than that of compound A, and those of the compounds of Examples 1 and 2 were also lower than those of compound A.

Judging as a whole from these results and the results of Experiment 1, the inhibitory effects of the compounds of Examples 1,2 and 43 on the rhythmic contractions of the bladder (micturition reflex) are extremely separated from the effects laterals such as central depression and inhibition of the spinal reflex, and toxicity, compared with those of compound A.

As is clear from the above results, the compound of the formula (I), a pharmaceutically acceptable acid addition salt thereof, and an N-oxide derivative thereof (at this point, occasionally referred to as "the compound of the present invention ") exhibit a potent inhibitory effect on the mitraltion reflex and show low toxicity, and with it, these compounds are used as agents for the treatment of frequent urination and urinary incontinence, particularly as a remedy for treatment of various conditions caused by the decreased bladder volume capacity (eg, unstable bladder, neurogenic bladder, chronic cystitis, chronic prostatitis, and pollaquisuria nervosa), which are induced by several factors.

The compounds of the present invention can be administered either orally, parenterally or rectally, but oral administration is preferable. The dose of the compounds of the present invention may vary in accordance with for example, the wide variety of compounds, the es of administration and the age conditions of the patients, but is usually in the range of 0.1-20 mg / kg. / day, preferably in the range of 0.4-10 mg / kg / day, which is administered once a day or divided into several units. The compounds of the present invention are usually administered in the form of a pharmaceutical composition which is prepared by mixing the active compounds with a pharmaceutically acceptable catalyst or diluent. The pharmaceutically acceptable catalyst or diluent can be at least any conventional, which are usually employed in the pharmaceutical field, and do not react with the compounds of the present invention. Suitable examples of the pharmaceutically acceptable catalysts or diluents are for example, lactose, inositol, glucose, mannitol, dextran, starch, partially pregelatinized starch, sucrose, magnesium aluminosilicate, synthetic aluminum silicate, crystalline cellulose, sodium carboxymethylcellulose, hydroxyprolyl starch, carboxymethylcellulose calcium, ion-exchange resin, methylcellulose, gelatin, gum arabic, hydroxypropylcellulose, substituted hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, alginic acid, sodium alginate, light anhydride of silicic acid, magnesium stearate, talc, carboxyvinyl polymer , titanium oxide, sorbitan fatty acid esters, sodium lauryl sulfate, glycerin, glycerin fatty acid esters, purified lanolin, glycerogelatine, macrogol, polysorbate, vegetable oils, wax, liquid paraffin, white gasoline, nonionic surfactants, propylene glycol and water.

The pharmaceutical composition is in, for example, tablets, capsules, granules, powders, syrups, suspensions, suppositories, cataplasms, and injection preparations. These preparations can be prepared by a conventional method. In the preparation of liquids, the compound of the present invention can be dissolved or suspended in water or in another convenient solvent, when administered. The tablets and granules can be covered by a conventional method.

These pharmaceutical compositions may contain the compound of the present invention at a ratio of more than 0.1%, preferably at a ratio of 1-70%. These pharmaceutical compositions may also contain other compounds also therapeutically effective.

BEST WAY TO CARRY OUT THE INVENTION The present invention is illustrated in more detail by the following Examples and Reference Examples, but can not be constructed to limit them.

The identification of the compounds is carried out by Elemento analysis, mass spectrum, IR spectrum, NMR spectrum, etc.

The following abbreviations can be used in the following examples and reference examples to simplify the description.

Me: Metilo Group Et: Ethyl Group Ph: Phenyl Group Fu: MA Fumaric Group: Maleic Acid OX: Oxalic acid A: Ethanol AC: Acetone AN: Acetonitrile DE: Diethyl ether EM: Ethyl methyl ketone IP: Isopropyl alcohol Example 1 Preparation of l- [2- (5-Fluoro-3,4-dihydro-2-naphthalenyl) ethyl] -pyrrolidine: To a solution of 5-fluoro-1,2,3-tetrahydro-2- [2- (l-pyrrolidinyl) ethyl] -l-naphthalenol (20. Og) in toluene (250 ml) was added p-toluenesulfonic acid monohydrate (16.2), and the mixture was refluxed overnight. After cooling, the reaction solution was washed successively with a solution of IN aqueous sodium hydroxide, water and a saturated sodium chloride solution, and dried over sodium sulfate anhydride, and concentrated under reduced pressure. The residue was purified by column chromatography with silica gel (eluent: toluene: ethyl acetate = 5: 1) and the fractions containing the desired compound were combined, concentrated under reduced pressure to give the desired compound (12.6 g) as an oily product.

The free base obtained above was dissolved in 30% of a solution of hydrogen chloride in ethanol (100 ml), and the mixture was concentrated under reduced pressure to remove the ethanol. To the residue was added diethyl ether, and the precipitated crystals were collected by filtration, and recrystallized from acetonitrile to give a hydrochloride of the desired compound (4.5 g) m.p. 194-198 ° C.

Example 2 Preparation of l- [2- (3, 4-dihydro-6,7-dimethyl-2-naphthalenyl) ethyl] -pyrrolidine: In a 30% solution of hydrogen chloride in ethanol (240 ml) were dissolved 1,2,3,4-tetrahydro-6,7-dimethyl-2- [2- (l-? Irrolidinyl) ethyl] -l-naphthalenol (24.0 g) and the mixture refluxed for one hour. The reaction solution was concentrated under reduced pressure, and the residue was dissolved in water, the sample was basified with potassium carbonate, and extracted with ethyl acetate. The extract was washed with water and a saturated aqueous sodium chloride solution, dried over sodium sulphate anhydride, and concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography with silica gel (eluent: chloroform: methanol = 10: 1), and the fractions containing the desired compound were combined, and concentrated under reduced pressure to give the desired compound (14.5 g) as an oily product.

The free base obtained above was treated with 30% of a solution of hydrogen chloride in ethanol in the same manner as in Example 1 to give a hydrochloride thereof, which was further recrystallized from ethanol to give a hydrochloride of the compound wanted. P.f. 212-214 ° C.

XH-M spectrum (200 MHz, (CD3) 2SO dppm): 1.75- 2.08 (m, 4H), 2.10-2.27 (m, 2H), 2.14 (s, 6H), 2.53-2.77 (m, 4H), 2.83-3.15 (brs, 2H), 3.15-3.39 (m, 2H), 3.39-3.68 (brs, 2H), 6.24 (S, 1H), 6.79 (s, lH), 6.88 (s, H), 10.85 (br s, 1H).

Examples 3-41 The corresponding 1, 2,3, 4-tetrahydro-2 - [α- (1-aminocyclic) alkyl] -l-naphthalene was treated in the same manner as in Example 1 or 2 to give the compounds as were listed in Table 6. 1,2,3,4-tetrahydro-2 - [α- (1-aminocyclic) alkyl] -l-naphthalene were prepared by treating the corresponding amine 1- [α- (1, 2, 3 -, 4-tetrahydro-l-oxo-2-naphthalenyl) cyclic alkanoyl which were obtained in Reference Examples 4-7 in the same manner as in Reference Example 8. Table 6 Ex. P. Solv. for No. Rl R2 m. P q Q recrystal. 3 HH 3 5 MA 105-106 IP 4 HH 4 4 HCl 142-144 AN 5 HH 4 4 FU 125-128 AN 6 HH 4 5 OX 151-153 A 7 HH 5 5 or ox 144-145 A 8 H 5-F 2 5 MA-3/4 H, 0 120-121 IP 9 H 5-F 2 6 HCl 201-205 AN 10 H 6-F 2 4 HCl 181-185 A-AC 11 H 6-F 2 5 MA-1 / 2 H20 118-119 IP 12 H 7-F 2 4 HC1-3 / 20 H20 207-209 IP 13 H 7-F 2 5 MA-1/2 H20 106-107 IP 14 H 5-C1 2 4 HCl 168 -169 MS 15 H 7-C1 2 4 HCl 223-227 EM 16 'H 7-C1 2 5 MA 127-129 AN 17 H 5-Me 2 4 HCl 182-184 EM 18 H 5-Me 2 5 MA 170-171 A 19 H 6-Me 2 5 MA 107-108 IP 20 H 7-Me 2 4 MA 92-93 IP 21 H 7-Me 2 5 MA 134-136 IP 22 H 7-Eí 2 4 HCl 196-198 EM 23 H 7-Et 2 5 OX 175-177 A 24 H 5-OMe 2 4 MA 117-119 IP 25 H 5 -OMe 4 4 FU 208-214 AN 26 H 5-OMe 2 5 MA 131-132 IP Ex. Mp Solv. for No. Rl R2 P q Q CC) recrystal. 27 H 3-OEt 2 4 HCl 182-186.? N 28 H 5 -OEt 2 5 MA 158-160 A 29 H 5-OMe 2 6 OX 172-174 A 30 H 5-OMe 3 5 OX 132-134 A 31 H 5-OMe 4 5 MA 109-110 A 32 H 5-OMe 5 5 OX 135-140 A 33 H 6-OMe 2 5 MA 1 16-117 IP 34 H 7-OMe 2 5 OX 179-180 A 35 H 5-OH 2 5 MA 151- 152 MS 36 7-F 6-F 2 4 HCl 198-201 MS 37 7-C1 6-C1 2 4 HCl 229-230 MS 38 7-OEt 6-F 2 5 HCl 205 -210.? N 39 7-Me 5-Me 2 4 HCH / 10 H, OR 178-182.? N 40 7-Me 5-Me 2 5 HCM / 5 H2O 229-233 AN il 7-Me 6-Me 2 3 MA 1 16-119.? N 42 7-Me 6-Me • >; 5 MA 157- 158 IP 43 7-Me 6-Me 2 5 HCl 244-246.? N 44 7-Me 6-Me 2 6 HCl 238-240.? N 45 7-Me 6-Me 2 7 HCM / IO H, O 208-213 AN 46 '' 7-Et 6-Et 4 FU 108-1 11.? N 47 7- (CH 2) 3-6 2 4 FU 178-183.? N 48 7- (CH 2) 3 -6 2 5 MA 155-157 A 49 7-OCH2O-6 2 4 HCl 207-212 EM E j 'emplo! fifty Preparation of l- [2- (3,4-Dihydro-6,7-dimethyl-2-naphthalenyl) ethyl] -2,5-dimethylpyrrolidine: 1 - [(1, 2,3,4-tetrahydro-6,7-dimethyl-1-oxo-2-naphthalenyl) acetyl] -2,5-dimethylpyrrolidine were treated in the same manner as in Example Reference 8 to give 1, 2,3, 4-tetrahydro-6,7-dimethyl-2- [2- (2, 5-dimethyl-l-pyrrolidinyl) ethyl] -l-naphthalenol as an oily product, which was further treated in the same manner as in Example 2 to give a hydrochloride of the desired compound, mp 227-229 ° C (recrystallized from acetonitrile).

Example 51 Preparation of l- [2- (3,4-dihydro-6,7-dimethyl-2-naphthalenyl) ethyl] -2- (methoxymethyl) pyrrolidine: l - [(1, 2, 3, 4-tetrahydro-6,7-dimethyl-l-oxo-2-naphthalenyl) acetyl] -2- (methoxymethyl) pyrrolidine were treated in the same manner as in Reference Example 8 to give 1, 2, 3, 4-tetrahydro-6,7-dimethyl-2- [2- (2- (methoxymethyl) -l-pyrrolidinyl) ethyl] -l-naphthalenol as an oily product, which was further treated in the same manner as in Example 1 to give a fumarate of the desired compound, mp. 166-168 ° C (recrystallized from acetonitrile).

Example 52 Preparation of l- [2- (5,7-difluoro-3,4-dihydro-2-naphthalenyl) ethyl] -pyrrolidine: To the borane complex with 5,7-difluoro-1,3,3-tetrahydro -2 [-2- (l-pyrrolidinyl) ethyl] -l-naphthalenol, which was obtained in the following Reference Example 9, were added p-toluenesulfonic acid monohydrate (4.1 g) and toluene (54 ml), and the mixture was refluxed for three hours. After cooling the reaction solution was washed with 10% aqueous sodium hydroxide solution, dried over sodium sulfate anhydride, and concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography with silica gel (eluent: chloroform: ethanol = 50: 1), and the fractions containing the desired compound were combined and concentrated under reduced pressure to give the desired compound (2.0 g) as a oily product. The product further obtained was treated with oxalic acid in ethanol in the conventional manner to give an oxalate thereof, which was further recrystallized from acetonitrile to give an oxalate of the desired compound, m.p. 146-149 ° C.

The borane complex with 5-fluor-l, 2,3,4-tetrahydro-2- [2- (1-pyrrolidinyl) ethyl] -l-naphthalenol, which was obtained in the following Reference Example 12, was treated with the same way with in the previous Example to give the compound of Example 1.

Examples 53-57 Borane complexes with the corresponding 1, 2, 3, 4-tetrahydro-2- [2- (1-pyrrolidinyl) ethyl] -l-naphthalenol, which were obtained in the same manner as in reference example 9 described above, were treated the same form as in example 52 to give the compounds as listed in Table 7.

Table 1 .

Ex. No. Rl R2 R * m.p. CC) Solv- P ^ 3 recrist. 53 H 5 -FF HCl 203-205 EM 54 6-F 5-FH HCl 202-204 EM 55 8-F 5-FH OX 161-165 AN 56 H 7-COOMe H HCl 191-192 EM 57 7-Me 6 -Me F HCl 204-206 EM Example 58 Preparation of l- [2- (3,4-dihydro-7-methoxy-2-naphthalenyl) ethylj-pyrrolidine: 3,4-dihydro-7-methoxy-2-naphne-methylene methanesulfonate, which was obtained in Example of Reference 10 described above, acetonitrile (70 ml) and pyrrolidine (3.5 g) were added, and the mixture was refluxed for six hours. The mixture was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography on silica gel (eluent, chloroform: ethanol = 50: 1). The fractions containing the desired compound were combined, and concentrated under reduced pressure to give the desired compound (2.5 g) as an oily product.

The free base obtained above was treated with 30% of a solution of hydrogen chloride in ethanol in the same manner as in Example 1 to give a hydrochloride thereof, which was further recrystallized from ethyl methyl ketone to give a hydrochloride of the desired compound, mp 161-163 ° C.

Examples 59-61 The corresponding 3,4-dihydro-naphthalethyl methanesulfonate, which was obtained in the same manner as in Reference Example 10 described above, was treated in the same manner as in the Example 58 to give the following compounds.

(Example 59) l- [2- (3,4-Dihydro-2-naphthalenyl) ethyl] pyrrolidine hydrochloride, m.p. 205-207 ° C (recrystallized from ethanol - diethyl ether) (Example 60) l- [2- (3, 4-dihydro-2-naphthalenyl) ethyl] -3-hydroxypyrrolidine hydrochloride, m.p. 126-128 ° C (recrystallized from ethylmethyl ketone) (Example 61) 3-fluoro-l- [2- (3, 4-dihydro-6,7-dimethoxy-2-naphthalenyl) ethyl] -pyrrolidine hydrochloride, m.p. 202-205 ° C (recrystallized from ethylmethyl ketone) Example 62 Preparation of l- [2- (3,4-dihydro-6,7-dimethoxy-2-naphthalenyl) ethyl] -pyrrolidine: 1,2,4,4-tetrahydro-2- (2-methanesulfonyloxyethyl) methanesulfonate - 6-dimethoxy-1-naphthalenyl, which was obtained in Reference Example 11 described below, were added acetonitrile (72 ml) and pyrrolidine (4.5 g) and the mixture was refluxed for six hours. The mixture was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography on silica gel (eluent, chloroform: ethanol = 50: 1). The fractions containing the desired compound were combined and concentrated under reduced pressure to give the desired compound (3.5 g) as an oily product. The free base obtained above was treated with 30% solution of hydrogen chloride in ethanol in the same manner as in Example 1 to give a hydrochloride thereof, which was further recrystallized from ethylmethyl ketone to give a hydrochloride of the desired compound, mp 204-206 ° C.

Examples 63-70 The corresponding methanesulfonates, 1,2,3,4-tetrahydro-2-2-methanesulfonyloxyethyl-1-naphthalenyl, which were obtained in the same manner as in Reference Example 11 described below, were in the same manner as in Example 62 to give the compounds as listed in Table 8. The solvent for recrystallization is diethyl ether for the compound of Example 63, and ethylmethyl ketone for the compounds of all the remaining examples.

Table 8 Ex. No. Rl R2 R3 R < R5 m.p. Q CC) 63 H 5-F H OH H - 74-78 64 6-OMe H H H H HCl 225-227 65 H H 7-Ph H H HCl 194-196 66 7-Me 6-Me H OH H HCl 191-194 67 7-Me 6-Me H F F HCl 207-209 68 7-OMe 6-Me H H H HCl 220-221 69 7-OCH2CH2-6 H H H HCl 206-209 70 8-OMe 7-OMe 6-OMe H H HCl 184-186 Example 71 Preparation of l- [2- (3, 4-dihydro-7-hydroxymethyl-2-naphthalenyl) ethyl] -pyrrolidine: l- [2- (3, 4-Dihydro-7-methoxycarbonyl-2-naphthalenyl) ethyl] pyrrolidine (1.0 g) were dissolved in tetrahydrofuran (20 ml), and 1.5 M of a solution of aluminum hydride diisobutyl in toluene (7.0 ml) under ice-cooling, and the mixture was stirred for one hour. To the solution of the reaction was added water in drop form to disintegrate the excessive amount of the reducing agent, and the mixture extracted with ethyl acetate. The extract was dried over sodium sulfate anhydride, and concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (eluent; chloroform: ethanol = 30: 1), and the fractions containing the desired compound were combined, and concentrated under reduced pressure to give the desired compound (0.8 g) as an oily product.

The free base obtained above was treated with a 30% solution of hydrogen chloride in ethanol in the same manner as in Example 1, to give a hydrochloride thereof, which was further recrystallized from ethyl methyl ketone to give a hydrochloride of the desired compound, mp 193-194 ° C. Spectrum? H-NMR (200 MHz, CD13, dppm): 1.72 (m, 1H), 1.95-2.20 (m, 4H), 2.27 (t, 2H, J = 8.5), 2.72-2.91 (m, 6H), 3.15-3.29 (m, 2H), 3.75-3.94 (m, 2H), 4. 55 (d, 2H, J = 5), 6.28 (s, lH), 7.01 (s, lH), 7.05-7.17 (m, 2H), 12. 65 (m, lH).

Example 72 Preparation of l- [2- (3,4-dihydro-6-hydroxymethyl- 7-methyl-2-naphthalenyl) ethyl] pyrrolidine: l- [2- (3,4-Dihydro-6-methoxycarbonyl-7-methyl-2-naphthalenyl) ethyl] -? irrolidine was treated the same as in Example 71 to give the desired compound, m.p. 76-77 ° C (recrystallized from hexane-ether diethyl).

Example 73 Preparation of l- [2- (7-carboxy-3,4-dihydro-2-naphthalenyl) ethyl] -pyrrolidine: l- [2- (3,4-Dihydro-7-methoxycarbonyl-2-naphthalenyl) ethyl] pyrrolidine (1.0 g) were dissolved in ethanol (5 ml), and an aqueous sodium hydroxide solution (5.2) was added thereto. ml) and the mixture was stirred at 25 ° C for 6 hours. The mixture was concentrated under reduced pressure to remove the solvent, and the residue was acidified with 10% hydrochloric acid. The precipitated crystals were collected by filtration, and subjected to desalting using CHP-20P (resin of high porous polystyrene; 75-150 μm prepared by Mitsubishi Kasei Corporation) (eluent, water, then acetonitrile). The eluents were concentrated under reduced pressure, and the residue was recrystallized from ethyl ethyl ketone ketone to give the desired compound m.p. 202-203 ° C.

Spectrum ^ -NMR (200 MHz, (CD3) 2SO, dppm): 1.80- 2.10 (m, 4H), 2.28 (t, 2H, J = 7), 2.62 (t, 2H, j = 8), 2.85 (t, 2h, j = 8), 2.90-3.12 (m, 2H), 3.32 (t, 2H, J = 7), 3.41-3.65 (m, 2H), 6.44 (3,1H), 7.25 (d, 1H, J = 8), 7.60 (d, lH, J = l), 7.70 (dd, lH, J = 8, l), 10.56 ( m, lH), 12.80 (m, lH).

Example 74 Preparation of l- [2- (6-carboxy-3,4-dihydro-7-methyl-2-naphthalenyl) ethyl] pyrrolidine: l- [2- (3,4-Dihydro-6-methoxycarbonyl-7-methyl-2-naphthalenyl) ethyl] -pyrrolidine were treated in the same manner as in Example 73 to give a hydrochloride of the desired compound. p.f. 258-259 ° C (recrystallized from ethanoyl ethyl ketone ketone).

The initial compounds used in the above examples were prepared as follows.

Reference Example 1 Preparation of 1,2,3,4-tetrahydro-6,7-dimethyl-l-oxo-2-naphthalene acetic acid: (1) A mixture of 37% formalin (18g) and dimethylamine hydrochloride (18) g) were stirred at 25 ° C for 30 minutes, and stirred at 70 ° C for 30 minutes. The reaction temperature was elevated to 80 ° C, and acetic anhydride (80 ml) was added to the mixture as an anhydride drop. The reaction mixture was stirred at 80 ° C for one hour, and 3,4-dihydro-6,7-dimethyl-l (2H) -naphthalenone (26 g) was added thereto. The reaction temperature was raised to 90 ° C, and the mixture was stirred for 6 hours. The mixture was concentrated under reduced pressure to remove the solvent, and acetone was added to the residue. The precipitated crystals were collected by filtration, and washed with acetone to give 2-dimethylaminomethyl-3,4-dihydro-6,7-dimethyl-l (2H) -naphthalenone hydrochloride (39 g). (2) The Mannich base hydrochloride obtained above (39 g) was dissolved in ice water, and the mixture was basified with aqueous ammonia, and extracted with dichloromethane. The dichloromethane layer was washed with water, and dried over magnesium anhydride, and the resultant was concentrated under reduced pressure at a temperature below 40 ° C to remove the solvent. The residue was dissolved in acetone, and thereto was added dropwise methyl iodide (10.8 ml) with stirring under ice-cooling, and then heated to 25 ° C. The mixture was stirred for two hours. The crystals were collected by filtration, and washed with acetone to give 1, 2, 3, 4-tetrahydro-N, N, N, 6,7-pentamethyl-l-oxo-2-naphthalene-methanammonium iodide (46 g) . (3) the quaternary salt obtained previously (46 g) was dissolved in methanol (300 ml), and a solution of potassium cyanide (9.6 g) in water (80 ml) was added thereto, and the mixture was stirred at 25 °. C for three hours. The reaction mixture was concentrated under reduced pressure, and the residue was extracted with ethyl acetate. The ethyl acetate layer was washed with water and a saturated aqueous sodium chloride solution, and dried over magnesium sulfate anhydride. The resultant was concentrated under reduced pressure to remove the solvent to give 1, 2, 3, 4-tetrahydro-6,7-dimethyl-l-oxo-2-naphthalene-acetonitrile (22 g) as crystals. (4) The above acetonitrile compound (22 g) was dissolved in a mixture of concentrated hydrochloric acid (200 ml) and glacial acetic acid (200 ml), and the mixture was refluxed for 6 hours. To the reaction solution was added water, and the precipitated crystals were collected by filtration, washed with water, and recrystallized from ethyl methyl ketone to give the desired compound (16.5 g), m.p. 193-194 ° C.

IR spectrum (Kbr, cm "1): 1707, 1676 XH-NMR spectrum (200 MHz, CDl3 dppm): 181-2.24 (m, 2H), 2.27 (s, 3H), 2.29 (s, 3H), 2.38-2.56 (m, 1H), 2.89-3.15 (m, 4H), 7.02 (s, lH), 7.80 (s, lH), 10.50 (br 3, 1H).

Reference example 2 Preparation of 1, 2, 3, 4-tetrahydro-l-oxo-2-naphthalenepropane acid: (1) To a solution of diisopropylamine (16 ml) in tetrahydrofuran (350 ml) were added dropwise a solution of 1.6 M butyllithium in hexane (7 ml) under cooling at -78 ° C, and the mixture was stirred for 30 minutes. To the reaction mixture was added dropwise a solution of 3,4-dihydro-l (2H) -naphthalenone (16.5 g) in tetrahydrofuran (60 ml) for a period of about 20 minutes under cooling to -78 ° C. , and the mixture was stirred for 30 minutes. To the mixture was added dropwise a solution of ethyl 3-bromopropanoate (20.5 g) in tetrahydrofuran (60 ml) for a period of about 20 minutes, and then further stirred for 30 minutes. The reaction mixture was stirred overnight at 20 ° C, and diluted with diethyl ether. The mixture was washed successively with water, 5% aqueous sodium hydrogen carbonate solution, and 5% hydrochloric acid, and dried over magnesium sulfate anhydride. The resultant was concentrated under reduced pressure to remove the solvent to give ethyl 1,2,3,4-tetrahydro-l-oxo-2-naphthalenepropanoate (10.1 g) as an oily product. (2) The ethyl ester compound obtained above (10.1 g) was dissolved in ethanol (200 ml), and a solution of 2N aqueous sodium hydroxide (170 ml) was added thereto, and the mixture was refluxed for three times. hours. The mixture was concentrated under reduced pressure to remove the ethanol, and the aqueous layer was acidified with concentrated hydrochloric acid, and extracted with dichloromethane. The dichloromethane layer was washed with water, dried with magnesium sulfate anhydride, and concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (eluent, chloroform), and the fractions containing the desired compound were combined and concentrated under reduced pressure to give the desired compound (6.3 g) as an oily product.

The corresponding starting compounds were treated in the same manner as in the Reference Example to give 1, 2, 3, 4-tetrahydro-5-methoxy-1-oxo-2-naphthalenepropanoic acid as an oily product.

Reference Example 3 Preparation of 1, 2, 3, 4-tetrahydro-l-oxo-2-naphthalenbutanoic acid: (1) To a solution of diethyl carbonate (200 g) in toluene (800 ml) were added 60% sodium hydride (27.4 g), and the mixture was stirred at 50 ° C for 30 minutes, and to this was added in the form of water a solution of 3,4-dihydro-l (2H) -naphthalenol (50 g) in toluene (200 ml). The mixture was refluxed for one hour, and poured into ice water, and the mixture was neutralized with acetic acid. The toluene layer was collected, washed successively with a solution of aqueous potassium carbonate and water, dried over magnesium sulfate anhydride, and concentrated under reduced pressure. The residue was purified by distillation under reduced pressure to give ethyl 1, 2, 3, 4-tetrahydro-l-oxo-2-naphthalenecarboxylate (47 g) as an oily product, p.b. 135-145 ° C / 2 mmHg. (2) The ethyl carboxylate compound obtained above (32 g) was dissolved in tert-butanol (120), and potassium terbutoxide (25 g) was added thereto, and the mixture was refluxed for 30 minutes. The mixture was left to stand by cooling to 25 ° C, and thereto was added ethyl 4-bromobutanoate (34 g). The mixture was refluxed overnight, and concentrated under reduced pressure. Water was added to the residue, and the mixture was extracted with diethyl ether. The ether layer was washed with water, dried over magnesium sulfate anhydride, and concentrated under reduced pressure to give ethyl 2-ethoxy-carbonyl-l, 2,3,4-tetrahydro-l-oxo-2-naphthalene-butanoate (50 g ) as an oily product. (3) The ethyl butanoate compound obtained above was dissolved in ethanol (500 ml), thereto was added 30% of an aqueous potassium hydroxide solution (300 ml), and the mixture was refluxed overnight. The mixture was concentrated under reduced pressure to remove the ethanol, and the resultant was acidified with concentrated hydrochloric acid, and extracted with dichloromethane. The dichloromethane layer was washed with water, dried over magnesium sulfate anhydride, and concentrated under reduced pressure to remove the solvent to give the desired compound (23 g) as an oily product.

The corresponding starting compounds were treated in the same manner as in the above Reference Example to give the following compounds as an oily product. 1,2,3,4-Carboxy-5-methoxy-l-oxo-2-naphthalenebutanoic acid 1,2,3,4-tetrahydro-l-oxo-2-naphthalene pentanoic acid and acid 1, 2, 3, 4- tetrahydro-5-methoxy-l-oxo-2-naphthalene pentanoic Reference Example 4 Preparation of 1 - [(1,2,3,4-tetrahydro-6-methyl-l-oxo-2-naphthalenyl) -acetyl] piperidine: 1,2, 3, 4-tetrahydro-6-methyl-l-oxo-2-naphthaleacetic acid (7.0 g) and thionyl chloride (7 ml) were dissolved in chloroform (150 ml) and the mixture was subjected to reflux for one hour. After cooling, the mixture was concentrated under reduced pressure to remove the solvent, and the residue was dissolved in toluene (100 ml), and piperidine (8.2 g) was added dropwise under cooling with ice. The mixture was stirred at 25 ° C for one hour, washed successively with dilute hydrochloric acid and water, dried with magnesium sulfate anhydride, and concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography with silica gel (eluent: toluene: ethyl acetate = 10.1), and the fractions containing the desired compound were combined and concentrated under reduced pressure to give the desired compound (4.4 g) as an oily product.

The corresponding starting compounds were treated in the same manner as in the reference example to give 1 - [(1, 2, 3, 4-tetrahido-7-methyl-1-oxo-2-naphthalenyl) acetyl] piperidine as a product oily.

Reference Example 5 Preparation of 1 - [(1, 2, 3, 4-tetrahydro-6,7-dimethyl-l-oxo-2-naphthalenyl) -acetyl] pyrrolidine: to a solution of acid 1,2,3, 4-tatrahydro-6,7-dimethyl-l-oxo-2-naphthalene-acetic acid (8.0 g), pyrrolidine (3.8 g) and benzotriazol-1-yloxy-tris (dimethylamino) phosphonium hexafluorophosphate (BOP Reagent, 16.7 g) in dichloromethane (80 ml) were added dropwise triethylamine (3.8 g) at 25 ° C, and the mixture was stirred for three hours. The mixture was concentrated under reduced pressure to remove the solvent, and water and toluene were added to the residues, and the insoluble materials were removed by filtration. The toluene layer was collected, washed successively with IN aqueous sodium hydroxide solution, water and a saturated aqueous sodium chloride solution, and dried over sodium sulfate anhydride. The resultant was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography on silica gel (eluent: toluene-ethyl acetate = 10: 1); and the fractions containing the desired compound were combined, and concentrated under reduced pressure to give the desired compound (9.5 g) as an oily product.

IR spectrum (pure, cm "1): 1672.1638 Spectrum ^ -NMR (200 MHz, CD13, dppm): 1.76-2.09 (m, 5H), 2.26 (s, 3H), 2.28 (s, 3H), 2.17-2.40 (m, 2H), 2.76-3.28 (m , 4H), 3.36-3.66 (m, 4H), 7.00 (s, lH), 7.78 (s, lH) the 1,2,3,4-tetrahydro-1-oxo-naphthalene acetic acids obtained in the same manner as in Reference Example 1 and the cyclic amine compounds were treated in the same manner as in Reference Example 5 to give the compounds as listed in Table 9.

Table 9 R R2 q H 5 -F 4 H 5 -F 5 H 5 -F 6 H 6 -F 4 H 6 -F 5 H 7 -F 4 H 7 -F 5 H 5 -Cl 4 H 7-a 4 H 7 -C1 5 H 5 -Me 4 H 5 -Me 5 H 7 -Me 4 R R2 q H 7-Et 4 H 7-Et 5 H 5-OMe 4 H 5-OMe 5 H 5-OEt 4 H 5 -OEt 5 H 5-OMe 6 H 6-OMe 5 H 7-OMe 5 H 5 -OH 5 7-F 6-F 4 '7-C1 6-C1 4 7-OEt 6-F 5 7-Me 5-Me 4 7-Me 5-Me 5 7-Me 6-Me 3 7-Me 6 -Me 5 7-Me 6-Me 6 7-Me 6-Me 7 7-Et 6-Et 4 7- (CH 2) 3 -6 4 7- (CH 2) 3 -6 5 7-OCH 2 O-6 4 Reference example 6 The corresponding starting compounds were treated in the same manner as in Reference Example 5 to give the following compounds as an oily product. l - [(1,2,3,4-tetrahydro-6,7-dimethyl-oxo-2-naphthalenyl) acetyl] -2,5-dimethylpyrrolidine, and l - [(1, 2,3,4-tetrahydro- 6,7-dimethyl-oxo-2-naphthalenyl) acetyl] -2 (methoxymethyl) pyrrolidine.

Reference example 7 Preparation of l- [3- (1, 2, 3, 4-tetrahydro-l-oxo-2-naphthalenyl) propanoyl] -piperidine: to a solution of 1,2,3,4-tetrahydro-l-oxo- 2-naphthalenepropanoic (6.3 g) piperidine (3.7 g) and BOP reagent (15.4 g) in dichloromethane (150 ml) were added dropwise triethylamine (3.5 g) at 25 ° C, and the mixture was refluxed by three hours. The reaction mixture was washed successively with water and 10% hydrochloric acid, and dried with magnesium sulfate anhydride. The resultant was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography on silica gel (eluent; eluent: ethyl acetate 10: 1), and the fractions containing the desired compound were combined, and concentrated under reduced pressure to give the desired compound (7.1 g) as an oily product.

The corresponding starting compounds were treated in the same manner as in the previous reference example to give the following compounds. l- [3- (1, 2,3, 4-tetrahydro-5-methoxy-l-oxo-2-naphthalenyl) propanoyl] -piperidine, 1- [4- (1, 2,3,4-tetrahydro-1) -oxo-2-naphthalenyl) butanoylopyrrolidine, l- [4- (1, 2,3,4-tetrahydro-l-oxo-2-naphthalenyl) butanoyl] piperidine, l- [4- (1, 2, 3, 4-tetrahydro-5-methoxy-l-oxo-2-naphthalenyl) butanoyl] pyrrolidine, l- [4- (1, 2, 3, 4-tetrahydro-5-methoxy-l-oxo-2-naphthalenyl) butanoyl] piperidine, l- [5- (1, 2, 3, 4-tetrahydro-l-oxo-2-naphthalenyl) pedestrian] piperidine, and l- [5- (1, 2, 3, 4-tetrahydro-5-methoxy-l-oxo-2-naphthalenyl) penetoyl] piperidine.

Reference Example 8 Preparation of 1, 2, 3, 4-tetrahydro-6,7-dimethyl-2- [2- (1-pyrrolidinyl) ethyl] -l-naphthalenol: to a solution of 1 - [(1,2,3,4-tetrahydro-6,7-dimethyl-l-oxo-2-naphthalenyl) acetyl] pyrrolidine (9.5 g) in toluene (100 ml) were added in the form of drop with stirring a solution of 70% sodium bis (2-methoxyethoxy) aluminum hydride in toluene (29.0) under ice cooling, and the mixture was stirred at the same temperature for one hour, and stirred at 25 ° C for three hours. hours. The reaction mixture was cooled again with ice, and a solution of saturated aqueous sodium potassium tartrate (30 ml) was added dropwise thereto, and the mixture was stirred at the same temperature for 30 minutes in order to disintegrate the excess amount of the reducing agent. The organic layer was separated, washed successively with water and a saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydride. The residue was purified by column chromatography with silica gel (eluent: toluene: ethyl acetate = 10: 1), and the fractions containing the desired compound were combined, and concentrated under reduced pressure to give the desired compound (8.5 g. ) as an oily product.

IR spectrum (pure, cm "1): 3360, 3120 Spectrum ^ -RMN (200 MHZ, CD13, dppm): 1.46-1.95 (m, 9H), 2.20 (s, 3H), 2.23 (s, 3H), 2.44-2.94 (m, 9H), 4.31-4.41 (m , lH), 6.81 (s, lH), 7.42 (s, lH) Reference Example 9 Preparation of 5,7-difluoro-1,2,3,4-tetrahydro-2- [2- (l-pyrrolidinyl) ethyl] -l-naphthalenol: (1) a mixture of 5,7-difluoro-3,4-dihydro-l (2H) -naphthalenol, (3.2 g) glyoxylic acid monohydrate (1.6 g) and 85% phosphoric acid (3 ml) were heated with stirring at 90 ° C for four hours. After cooling, water was added to the reaction solution, and the precipitated crystals were collected by filtration, washed with water, and dried to give (5,6-difluoro-3,4-dihydro-l-oxo-2 ( 1H) -naphthalenylidene) acetic acid (4.2 g).

XH-NMR spectrum (200 MHz, CD13, dppm): 3. 00 (t, 2H, J = 7), 3.40-3.60 (m, 2H), 6.91 (t, 1H, J = l), 7.00-7.13 (m, lH), 7.58-7.66 (m, lH) (2) to a solution of the above acetic acid compound (4.2 g), pyrrolidine (1.9 g) and BOP reagent (8.6 g) in dichloromethane (40 ml) were added dropwise with stirring of triethylamine (2.0 g) to 25 ° C, and the mixture was stirred for three hours. The mixture was concentrated under reduced pressure to remove the solvent, and water and toluene were added to the residue. The insoluble materials were removed by filtration, and the toluene layers were separated, washed successively with IN aqueous sodium hydroxide solution, water, and a saturated aqueous sodium chloride solution, and dried with sodium sulfate anhydride. The resultant was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography on silica gel (eluent; ethyl acetate = 2: 1), and the fractions containing l - [(5,7- difluoro-1,2,3,4-tetrahydro-l-oxo-2-naphthalenylidene) acetyl] pyrrolidine were combined and concentrated under reduced pressure to give said amide compound (2.6 g) as an oily product.

XH-NMR spectrum (200 MHz, CD13, dppm =: 1.85- 2.06 (m, 4H), 2.96 (t, 2HJ = 7), 3.27-3.38 (m, 2H), 3.48-3.67 (m, 4H), 6.97 -7.09 (m, 1H), 7.16 (t, 1H, J = l), 7.56-7.64 (m, lH) (3) The amide compound obtained above (2.6 g) was dissolved in ethanol (130 ml), and a hydrogen gas was introduced through the mixture with stirring at 25 ° C by the use of a 10% carbon catalyst. palladium (0.3 g). After the theoretical amount of hydrogen gas was absorbed, the catalyst was removed by filtration. The filtrate was concentrated under pressure reduced to remove the solvent to give l - [(5,7-difluoro-1,2,3,4-tetrahydro-l-oxo-2-naphthalenyl) acetyl] pyrrolidine (2.3 g) as an oily product.

Spectrum ^ -RMN (200 MHz, CDl3, dppm): 1. 60 (s, 2H), 1.80-2.08 (m, 4H), 2.28-2.41 (m, 1H), 2.74-3.26 (m, 4H), 3.40-3.58 (m, 4H), 6.90-7.04 (m, 1H) ), 7.48-7.57 (m, H) (4) the obtained previous product (2.3 g) was dissolved in tetrahydrofuran (23 ml), and a 1M solution of borane-tetrahydrofuran complex in tetrahydrofuran was added to it in drop form ( 26 ml) under cooling with ice, and the mixture was stirred at 20 ° C overnight. To the reaction solution was added in the form of water methanol (26 ml) under cooling with ice, and the excess amount of the reducing agent was disintegrated. The mixture was concentrated under reduced pressure to remove the solvent to give the desired compound in the form of a complex with borane.

Reference example 10 Preparation of 3,4-dihydro-7-methoxy-2-naphthalethyl methanesulfonate: (1) a mixture of 3,4-dihydro-7-methoxy-2 (1H) -naphthalenone (5.9 g), benzoic acid (0.69 g) ethyl (triphenylphosphoranylidene) acetate (14.9 g) and toluene (20 ml) were subjected to reflux overnight. After cooling, the insoluble materials were removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with silica gel (eluent: hexane: ethyl acetate = 10.1), and the fractions containing ethyl, 3,4-dihydro-7-methoxy-2-naphthalene acetate were combined, and concentrated under reduced pressure to give said ester compound (6.2 g) as an oily product (2) the above ester compound (4.9 g) was dissolved in tetrahydrofuran anhydride (50 ml), and a 1M hydride solution was added thereto in drop form of diisobutylaluminum in toluene (48 ml) at -10 ° C, and the mixture was stirred at 0 ° C for one hour. Water was added to the reaction solution in the form of a drop, and the excess amount of the reducing agent was decomposed. The insoluble materials were removed by filtration, and the filtrate was extracted with ethyl acetate. The organic layer was dried with sodium sulfate anhydride and concentrated under reduced pressure to remove the solvent to give 3,4-dihydro-7-methoxy-2-naphthalene-ethanol (3.5 g) as an oily product.

XH-NMR spectrum (200 MHz, CDl3, dppm): 1.65 (br S, 1H), 2.25. { t, 2H, J = 8.5), 2.48 (t, 2H, J = 7.5), 2. 75 (t, 2H, J = 8.5), 3.78. { s, 3H), 3.75-3.84 (m, 2H), 6. 29 (s, lH), 6.59 (d, lH, J = 3), 6.66 (dd, 1H, J = 8, 3), 7. 01 (d, lH, J = 8) (3) The above ethanol compound (3.5 g) and triethylamine (2.8 g) were dissolved in dichloromethane (70 ml), and methanesulfonyl chloride (2.2 g) at 0 ° C was added thereto in the form of water. The mixture was stirred at the same temperature for one hour, and concentrated under reduced pressure to remove the solvent to give the desired compound as an oily product.

Reference Example 11 Preparation of 1,2,3,4-tetrahydro-2- (2-methanesulfonyloxyethyl) -6,7-dimethoxy-1-naphthalenyl methanesulfonate: (1) 3,4-dihydro-6,7-dimethoxy -l (2H) -naphthalenone (10.0 g) were dissolved in tetrahydrofuran (200 ml), and a 2M solution of diisopropylamine lithium in tetrahydrofuran (37 ml) at -70C was added dropwise thereto. The mixture was stirred for 30 minutes, and ethyl bromoacetate (10.5 g) was added thereto at -70 ° C. The mixture was stirred at the same temperature for two hours, and then stirred with diethyl ether. The ether layer was washed successively with water, 10% hydrochloric acid and 10% aqueous sodium hydrogen carbonate solution, and dried over sodium sulfate anhydride. The resultant was concentrated under reduced pressure to remove the solvent to give ethyl 1,2,3,4-tetrahydro-6,7-dimethoxy-l-oxo-2-naphthalene acetate (12.0 g) as an oily product. (2) the compound from the above ester (12.0) was dissolved in toluene (100 ml), and to this was added a 70% sodium bis (2-methoxyethoxy) -hydroxide solution in toluene (24 g) under cooling with ice, and the mixture was stirred at 25 ° C for 6 hours. To the reaction solution was added a solution of saturated aqueous sodium potassium tartrate under cooling with ice, and the mixture was stirred for one hour. The organic layer was separated, dried over sodium sulfate anhydride, and concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography with silica gel (eluent: chloroform: methanol = 20: 1), and fractions containing 1,2,3,4-tetrahydro-2- (2-hydroxyethyl) -6, 7-Dimethoxy-1-naphthalenol were combined and concentrated under reduced pressure to give said diol compound (3.6 g) as an oily product.

XH-NMR spectrum (200 MHz, CD13, dppm): 1.52- 2.02 (m, 5H), 2.45-2.90 (m, 4H), 3.71-3.95 (m, 2H), 3.84 (s, 3H), 3.89 (s) , 3H), 4.44 (d, lH, J = 7), 6.55 (s, lH), 7.05 (s, lH). (3) the above diol compound (3.6 g) and triethylamine (4.3) were dissolved in dichloromethane (72 ml), and methanesulfonyl chloride (3.8 g) was added dropwise under cooling with ice. The mixture was stirred for one hour, and concentrated under reduced pressure to remove the solvent to give the desired compound as an oily product.

Reference Example 12 Preparation of 5-fluoro-1,2,3,4-tetrahydro-2- [2- (1-pyrrolidinyl) ethyl] -l-naphthalenol: (1) A mixture of 5-fluoro-3,4-dihydro-l (2H) -naphthalenone (10 g), glyoxylic acid monohydrate (6.2 g) and 85% phosphoric acid (10 ml) was stirred at 90 °. C for three hours. After cooling, water was added to the reaction solution, and the precipitated crystals were collected by filtration, washed with water, and dried to give acid (5-fluoro-3,4-dihydro-l-oxo-2 ( 1H) -naphthalenylidene) acetic acid (13 g). (2) to a solution of the above acetic acid compound (20 g) and BOP reagent (45 g) in dichloromethane (200 ml) were added with stirring pyrrolidine (10 g), and then added in the form of drop triethylamine (19 g) ) under cooling with ice, and the mixture was stirred for three hours. The mixture was washed successively with water, 10% hydrochloric acid, 10% aqueous sodium hydroxide solution and a saturated aqueous sodium chloride solution, and dried with sodium sulfate anhydride. The resultant was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with silica gel (eluent: haxane: ethyl acetate = 2: 1) to give 5-fluoro-1, 2, 3, 4-tetrahydro-l-oxo-2-naphthalenylidene) acetyl) pyrrolidine (15 g) as an oily product. (3) the above amide compound (15.4 g) was suspended in ethanol (300 ml), and hydrogen gas was introduced through the mixture at 25 ° C with stirring using a palladium-carbon catalyst 105 (1.5). after the theoretical amount the hydrogen gas was absorbed, the catalyst was removed by filtration. The filtrate was concentrated under reduced pressure to remove the solvent, and the residue was purified by column chromatography with silica gel (eluent; hexane: ethyl acetate = 2: 1) to give 5-fluoro-1, 2, 3, 4-tetrahydro-l-oxo-2-naphthalenyl) acetyl) pyrrolidine (9.5) as an oily product.

Spectrum ^ -RM (200 MHz, CD13, dppm): 1.80- 2.10 (m, 5H), 2.24-2.45 (m, 2H), 2.80-3.03 (m, 2H), 3.08- 3.30 (m, 2H), 3.38 -3.54 (m, 4H), 7.15-7.34 (m, 2H), 7.78-7.85 (m, lH) (4) the previous product (9.5) was dissolved in tetrahydrofuran (100 ml) and a 1M solution of borane-tetrahydrofuran complex in tetrahydrofuran (138 ml) was added dropwise under ice cooling, and the mixture was stirred at 20 ° C at night. Methanol (100 ml) was added to the reaction mixture under cooling on ice, and the excess amount of the reducing agent was disintegrated. The mixture was concentrated under reduced pressure to remove the solvent to give the desired compound in the form of a complex with borane.

Example 75 Preparation of the tablets: l- [2- (5-Fluoro-3,4-dihydro-2-naphthalenyl) ethyl] pyrrolidine hydrochloride 15 corn starch 30 g Lactose 68 g Crystalline cellulose 30 g Hydroxypropyl cellulose 5 g light anhydrous silicic acid 1 9 magnesium stearate 1 g The above components are mixed and molded in a conventional manner, and the mixture is granulated, and compressed into cores of 1,000 tablets (each 150 mg). In addition, these tablet cores are covered by a conventional method using hydroxypropyl methylcellulose, macrogol, titanium oxide, talc and light anhydride of salicylic acid to give the coated film tablets.

Example 76 Powder preparation: l- [2- (3,4- 20 g dihydro-6,7-dimethyl-2-naphthalenyl) -ethyl] pyrrolidine D-mannitol hydrochloride 935 g hydroxypropyl cellulose 30 g magnesium stearate 10 g g silicic acid light anhydride The above components are mixed, and granulated to give 2% of the powder preparation.

INDUSTRIAL APPLICABILITY As explained above, the amine l- [- (3,4-dihydro-2-naphthalenyl) alkyl] cyclic derivatives of the formula (I), a pharmaceutically acceptable acid addition salt thereof and an N-oxide derivative thereof they exhibit an effective inhibitory effect on the reflex of micturition, and a low toxicity, and with it, these compounds are useful as agents for the treatment of frequent urination and urinary incontinence, or as a remedy for the treatment of various conditions caused by the Decrease in the volume capacity of the bladder, which are induced by several factors.

Claims

1. A compound of the formula (I) characterized norpue 1 and R2 are the same or different and each a hydrogen atom, a halogen atom, a hydroxy group, an alkyl group of 1-5 carbon atoms, an alkoxy group of 1-3 carbon atoms, a group hydroxymethyl, a formyl group, a carboxyl group, or an alkoxy group of 1-3 carbon atoms, or when R1, and R2 are bonded with carbon atoms, become adjacent to each other, then R1 and R2 may combine to form a methylenedioxy group, an ethyleneoxy group (-CH2CH20-), a trimethylene group, or a tetramethylene group, R3 is a hydrogen atom, a halogen atom, a trifluoromethyl group, an alkyl group of 1-5 carbon atoms, an alkoxy group of 1-3 carbon atoms, or a phenyl group, R4 is a hydrogen atom, a halogen atom, a hydroxy group, an alkyl group of 1-3 carbon atoms or a methyl group (alkoxy of 1-2 carbon atoms), R5 is a hydrogen atom, a halogen atom, an alkyl group, or a methyl group (alkoxy 1-2 carbon atoms), or when the bond of R4 and R5 with a carbon atom other than those adjacent to the nitrogen atom, then R4 and R5 can be combined to form an oxo group, p is an integer from 2 to 6, and q is an integer from 3 to 7, Assuming that when p is 2, and q is 5, then R ^ R ^ R ^ R4 and R5 are not hydrogen atoms simultaneously, or a pharmaceutically acceptable acid addition salt thereof, or an N-oxide derivative thereof.

2. The compound according to claim 1, characterized in that R1 and R2 are the same or different and each a hydrogen atom, a halogen atom, a hydroxy group, a methyl group, an ethyl group, a propyl group, a methoxy group , an ethoxy group, a hydroxymethyl group, a carboxyl group, a methoxycarbonyl group, or an ethoxycarbonyl group, and R3 is a hydrogen atom, or a pharmaceutically acceptable acid addition salt thereof, or an N-oxide derivative thereof .

3. The compound according to claim 2, characterized in that R 2 is a hydrogen atom, a halogen atom, a hydroxy group, or a methyl group, and R 5 is a hydrogen atom or a methyl group, or R 4 and R 5 are combined to form an oxo group, or an acid addition salt thereof, pharmaceutically acceptable.

4. The compound according to claim 3, characterized in that the bonds of R1 and R2 are to position 7 and position 6, respectively, and are the same or different and each a methyl group, an ethyl group, a methoxy group, a group ethoxy, or a hydroxymethyl group, R4 and R5 are the same or different and each a hydrogen atom or a methyl group, p is an integer from 2 to 5, and q is an integer from 3 to 7, or a salt of pharmaceutically acceptable acid addition thereof.

5. The compound according to claim 4, characterized in that R4, and R5 are both hydrogen atoms, p is 2.3 or 4, and q is 4 or 5, or a pharmaceutically acceptable acid addition salt thereof.

6. The compound according to claim 3, characterized in that R1 is a hydrogen atom, R2 is a halogen atom, or R1 or R2 are each a halogen atom at position 7 and position 6, respectively, R4 and R5 are the same or different and each a hydrogen atom or a methyl group, p is an integer from 2 to 5, and q is an integer from 3 to 7, or a pharmaceutically acceptable acid addition salt thereof.

7. The compound according to claim 6, characterized in that the halogen atom is a fluorine atom, R4 and R5 are hydrogen atoms, p is 2.3, or 4, and q is 4 or 5, or an addition salt thereof, pharmaceutically acceptable.

8. A compound of the formula (la): characterized in that Rla and R2a are the same or different, and each a methyl group, an ethyl group, a methoxy group, an ethoxy group, or a pharmaceutically acceptable acid addition salt or hydroxymethyl group thereof.

9. The compound according to claim 8, characterized in that it is selected from l- [2- (3, 4-dihydro-6,7-dimethoxy-2-naphthalenyl) ethyl] pyrrolidine, l- [2- (3,4-dihydro-7-methoxy-6-methyl-2- naphthalenyl) ethyl] pyrrolidine, l- [2- (3,4-dihydro-6-hydroxymethyl-7-methyl-2-naphthalenyl) ethyl] pyrrolidine, and l- [2- (6,7-Diethyl-3,4-dihydro-2-naphthalenyl) ethyl] pyrrolidine, or a pharmaceutically acceptable acid addition salt thereof.

10. l- [2-3,4-Dihydro-6,7-dimethyl-2-naphthalenyl] ethyl] pyrrolidine or a pharmaceutically acceptable addition salt thereof.

11. l- [2- (5-Fluoro-3,4-dihydro-2-naphthalenyl) ethyl] pyrrolidine, or a pharmaceutically acceptable addition salt thereof. 12. A process for the preparation of a compound of the formula (I): wherein R 1, R 2, R 3 R 4, R 5 P Y q are the same as defined in claim 1, or a pharmaceutically acceptable acid addition salt thereof, or an N-oxide derivative thereof which Droceso is characterized in that it comprises: (a) subjecting a compound of the formula (II): wherein R1, R2, R3, R4, R5, p and q are the same as defined in claim 1, by dehydration, or (b) reacting a compound of the formula

(III) wherein R1, R2, R3 and p are the same as defined in claim 1, X and Y are the same or different and each a reactive ester residue of an alcohol, and Z is a hydrogen atom, or Y and Z can be combined to form a bond, with a compound of the formula (IV): wherein R4, R5 and q are the same as defined in claim 1, optionally subjected to the product wherein R1 and / or R2 are an alkoxycarbonyl group of 1-3 carbon atoms to reduction by hydrolysis to become a compound wherein R1 and / or R2 are a formyl group, a hydroxymethyl group, or a carboxyl group, and / or followed to optionally convert the product to a pharmaceutically acceptable acid addition salt thereof or to an N-oxide derivative thereof.

13. The method according to claim 13, characterized in that the final product is a compound as claimed in any of claims 2 to 11.

14. A pharmaceutical composition characterized in that it comprises as an active ingredient a compound as set out in any of the claims 1 to 11, and a pharmaceutically acceptable catalyst or diluent.

15. An agent for the treatment of frequent urination and urinary incontinence, characterized in that they comprise as an active ingredient a compound as set forth in any of claims 1 to 11. SUMMARY OF THE INVENTION Derivative amine l - [α- (3,4-dihydro-2-naphthalenyl) alkyl] cyclic of the formula (I): wherein R1 and R2 are H, halogen, OH, alkyl, alkoxy, hydroxymethyl, etc. OR R1 and R2 combine to form methylenedioxy, trimethylene, etc. R3 is H, etc., R4 is H, OH, alkyl, etc., R5 is H, alkyl, etc., p is an integer from 2 to 6, and q is an integer from 3 to 7, assuming that when p is 2, and q is 5, R1, R2, R3, R4 and R5 are not simultaneously H, or salts thereof, or an N-oxide derivative thereof, or a process for the preparation thereof, or a pharmaceutical composition It contains the same. The compounds of the present invention show a potent inhibitory effect on the myocardial reflex and are used as agents for the treatment of frequent urination and urinary incontinence.